<p>Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma</p>
Cited by 56
Related Papers
Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy
|International Journal of Nanomedicine|2017|95
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
|Journal of Hematology & Oncology|2016|80
Overexpression of RASD1 inhibits glioma cell migration/invasion and inactivates the AKT/mTOR signaling pathway
|Scientific Reports|2017|36
CacyBP/SIP protein is important for the proliferation of human glioma cells
|IUBMB Life|2014|35
MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR‐induced NF‐κB activation
|Journal of Cellular and Molecular Medicine|2020|32